biguanides has been researched along with Metabolic Diseases in 3 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dvorácskó, S | 1 |
| Herrerias, A | 1 |
| Oliverio, A | 1 |
| Bhattacharjee, P | 1 |
| Pommerolle, L | 1 |
| Liu, Z | 1 |
| Feng, D | 1 |
| Lee, YS | 1 |
| Hassan, SA | 1 |
| Godlewski, G | 1 |
| Cinar, R | 1 |
| Iyer, MR | 1 |
| Waltenberger, B | 1 |
| Mocan, A | 1 |
| Šmejkal, K | 1 |
| Heiss, EH | 1 |
| Atanasov, AG | 1 |
| Frol'kis, AV | 1 |
2 reviews available for biguanides and Metabolic Diseases
| Article | Year |
|---|---|
Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.
Topics: Biguanides; Biological Products; Cardiovascular Diseases; Drug Discovery; Humans; Hydroxymethylgluta | 2016 |
[Inhibition of intestinal absorption as a principle of the treatment of metabolic diseases].
Topics: Animals; Anticholesteremic Agents; Biguanides; Deferoxamine; Dogs; Humans; Intestinal Absorption; Li | 1989 |
1 other study available for biguanides and Metabolic Diseases
| Article | Year |
|---|---|
Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders.
Topics: AMP-Activated Protein Kinases; Animals; Biguanides; Cannabinoid Receptor Antagonists; Cannabinoids; | 2023 |